Fulltime
Remarkable NMR Achievement in Collaboration with ESSA Pharma
The androgen receptor (AR) pathway drives most metastatic, castration-resistant prostate cancers (mCRPC). Anti-androgen resistance mechanisms include AR gene amplification, C-terminal ligand-binding domain (LBD) mutations and expression of constitutively-active truncated AR splice variants lacking…
Scientist in NMR-based RNA Drug Discovery (PhD)
Fulltime
Discovery on Target
In person Jan Schultz (Managing Director BD) has participated in Discovery on Target, the industry’s preeminent event on novel drug targets and technologies for drug discovery professionals. The conference highlighted advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging…